Hayward Kelly L, Weersink Rianne A
Centre for Liver Disease Research, Faculty of Medicine The University of Queensland, Translational Research Institute Brisbane QLD Australia.
Department of Gastroenterology and Hepatology Princess Alexandra Hospital Brisbane QLD Australia.
Hepatol Commun. 2020 Oct 10;4(11):1562-1577. doi: 10.1002/hep4.1612. eCollection 2020 Nov.
Patients with chronic liver disease (CLD) are becoming increasingly complex due to the rising prevalence of multimorbidity and polypharmacy. Medications are often essential to manage the underlying liver disease, complications of cirrhosis and portal hypertension, and comorbidities. However, medication-related problems (MRPs) have been associated with adverse patient outcomes, including hospitalization and mortality. Factors that can contribute to MRPs in people with CLD are variable and often entwined. This narrative literature review discusses key barriers and opportunities to modify risk factors and improve medication-related outcomes for people with CLD.
由于合并症和联合用药的患病率不断上升，慢性肝病（CLD）患者正变得越来越复杂。药物治疗对于控制潜在的肝脏疾病、肝硬化和门静脉高压并发症以及合并症往往至关重要。然而，药物相关问题（MRP）与不良患者结局相关，包括住院和死亡。导致CLD患者出现MRP的因素各不相同且常常相互交织。这篇叙述性文献综述讨论了改变危险因素以及改善CLD患者药物相关结局的关键障碍和机遇。
